Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®

Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment [6] - The company is headquartered in Palo Alto, California [8] Product Launch - Scilex launched GLOPERBA® on June 10, 2024, which is an FDA-approved prophylactic treatment for painful gout flares in adults [4][11] - GLOPERBA® is the first oral liquid medicine for the prophylaxis of gout flares, with a wholesale acquisition cost (WAC) price of $595 per bottle [11] Market Opportunity - Gout affects an estimated 9.2 million people in the United States, with increasing cases leading to higher treatment requirements [11] - The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028, indicating a significant unmet need in this area [11] Distribution and Stocking Arrangements - Many national pharmacy chains and independent pharmacies have begun stocking GLOPERBA® [4] - Scilex is negotiating similar stocking arrangements with additional pharmacy chains in the U.S. to ensure broad access and supply [11] Existing Product Portfolio - Scilex's commercial products include ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and GLOPERBA® for gout [6] - The company has three product candidates in development: SP-102 (SEMDEXA™), SP-103, and SP-104, targeting various pain management needs [7]